Artwork

内容由TheBody.com提供。所有播客内容(包括剧集、图形和播客描述)均由 TheBody.com 或其播客平台合作伙伴直接上传和提供。如果您认为有人在未经您许可的情况下使用您的受版权保护的作品,您可以按照此处概述的流程进行操作https://zh.player.fm/legal
Player FM -播客应用
使用Player FM应用程序离线!

A Closer Look at Egrifta, a Newly Approved Treatment for HIV-Associated Belly Fat Gain (Lipohypertrophy)

31:00
 
分享
 

Manage episode 127184 series 2246
内容由TheBody.com提供。所有播客内容(包括剧集、图形和播客描述)均由 TheBody.com 或其播客平台合作伙伴直接上传和提供。如果您认为有人在未经您许可的情况下使用您的受版权保护的作品,您可以按照此处概述的流程进行操作https://zh.player.fm/legal
On Nov. 10, Egrifta (tesamorelin) became the first drug approved in the U.S. to treat unusual fat gain, or lipohypertrophy, in people with HIV. In our latest episode of This Month in HIV, we talk with noted HIV researcher Daniel Berger, M.D., about how Egrifta works, who should take it, and what else we know to date about the treatment of lipohypertrophy.
  continue reading

77集单集

Artwork
icon分享
 
Manage episode 127184 series 2246
内容由TheBody.com提供。所有播客内容(包括剧集、图形和播客描述)均由 TheBody.com 或其播客平台合作伙伴直接上传和提供。如果您认为有人在未经您许可的情况下使用您的受版权保护的作品,您可以按照此处概述的流程进行操作https://zh.player.fm/legal
On Nov. 10, Egrifta (tesamorelin) became the first drug approved in the U.S. to treat unusual fat gain, or lipohypertrophy, in people with HIV. In our latest episode of This Month in HIV, we talk with noted HIV researcher Daniel Berger, M.D., about how Egrifta works, who should take it, and what else we know to date about the treatment of lipohypertrophy.
  continue reading

77集单集

Wszystkie odcinki

×
 
Loading …

欢迎使用Player FM

Player FM正在网上搜索高质量的播客,以便您现在享受。它是最好的播客应用程序,适用于安卓、iPhone和网络。注册以跨设备同步订阅。

 

快速参考指南

边探索边听这个节目
播放